Feedback
Settings

Settings

Goto Application

986,073 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 98,608
1.WO/2026/007662NUCLEIC ACID DELIVERY VECTOR TARGETING LIVER PARENCHYMAL CELLS AND USE THEREOF
WO - 08.01.2026
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No PCT/CN2025/100587 Applicant DSCILAB.CO., LTD Inventor CUI, Zhiping
The present invention relates to a material for local drug delivery and use thereof. Specifically provided is a nanoparticle composition. The nanoparticle composition comprises a cationic lipid, a PEG lipid, and a structural lipid, wherein the lipid component of the PEG lipid is 1.0-5.5 mol%, or a range between any two of the described values. The nanoparticle composition of the present invention is delivered only at the site of administration.
2.WO/2026/008022METHOD FOR MEASURING VIRUS TITER OF LIVE ATTENUATED MEASLES, MUMPS, RUBELLA AND VARICELLA COMBINED VACCINE
WO - 08.01.2026
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
 Appl.No PCT/CN2025/106875 Applicant SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD. Inventor XU, Ran
Provided are a primer-probe combination for real-time quantitative PCR, a related kit, and a method for using primers to measure the titers of measles, mumps and varicella virus pathogens. The method is applicable to clinical and laboratory detection, is fast and convenient, and has high sensitivity.
3.WO/2026/008787COMPOSITIONS
WO - 08.01.2026
Int.Class C12Q 1/6806
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction assay
 Appl.No PCT/EP2025/069027 Applicant CPTX GMBH Inventor BERGER, Nadja
Provided herein is a DNA-based nanostructure at least a first plurality of virus-binding moieties, wherein each virus-binding moiety of the at least first plurality of virus- binding moiety is a neuraminidase inhibitor. Also provided herein is a DNA-based nanostructure at least a first plurality of virus-binding moieties, wherein each virus- binding moiety of the at least first plurality of virus-binding moiety is a neuraminidase- binding moiety and/or a haemagglutinin-binding moiety. Also provided herein is a self- assembling DNA-based building block formed by a single-stranded DNA template strand and a set of oligonucleotides complementary to said single-stranded DNA template, wherein: each of the oligonucleotides is either complementary to one contiguous DNA sequence stretch or to at least two non-contiguous DNA sequence stretches on said single-stranded DNA template; and the self-assembling DNA-based building block comprises at least one first virus-binding moiety, wherein the first virus- binding moiety is a neuraminidase-binding moiety and/or a haemagglutinin-binding moiety. Also provided herein is a DNA-based nanostructure wherein the DNA-based nanostructure comprises at least five self-assembling DNA-based building blocks; each of the self-assembling DNA-based building blocks is formed by a single-stranded DNA template strand and a set of oligonucleotides that are at least partially complementary to said single-stranded DNA template; and wherein each of the oligonucleotides is either complementary to one contiguous DNA sequence stretch or to at least two non- contiguous DNA sequence stretches on said single-stranded DNA template. Also provided herein are associated methods, uses, compositions, and kits.
4.WO/2026/009972COMPOSITION FOR TREATING CONGENITAL GPI DEFICIENCY
WO - 08.01.2026
Int.Class C12N 15/864
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
864Parvoviral vectors
 Appl.No PCT/JP2025/024137 Applicant THE UNIVERSITY OF OSAKA Inventor MURAKAMI, Yoshiko
The present disclosure provides an AAV vector including: (a) a promoter including a nucleotide sequence having approximately 90% or more identity to a nucleotide sequence of SEQ ID NO: 3 and having activity greater than or equivalent to that of a promoter comprising the nucleotide sequence of SEQ ID NO: 3; and (b) a polynucleotide encoding PIGO.
5.WO/2026/010722COMPOSITIONS AND METHODS FOR REGULATING MAPT
WO - 08.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/033604 Applicant VOYAGER THERAPEUTICS, INC. Inventor SAH, Dinah Wen-Yee
The disclosure relates to small interfering RNA (siRNA) molecules targeting MAPT and adeno-associated viral (AAV) particles encoding the same for treating tauopathies.
6.WO/2026/011097ANTIBODY DRUG CONJUGATES COMPRISING TCR-VBETA SPECIFIC THERAPEUTIC MOLECULES AND USES THEREOF
WO - 08.01.2026
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
 Appl.No PCT/US2025/036384 Applicant YALE UNIVERSITY Inventor GIRARDI, Michael
Provided are immunoconjugates comprising an antibody or antigen binding fragment to a Vβ region of a T cell receptor and a chemotherapeutic drug or cytotoxic agent, and composition thereof. Also provided are methods for treating a disease such as cancer or an autoimmune disease using immunoconjugates of the present disclosure.
7.WO/2026/007196ANTIBODY SPECIFICALLY BINDING TO FGFR2B AND DRUG CONJUGATE THEREOF
WO - 08.01.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/CN2024/110924 Applicant ABIOTECH PHARMACEUTICAL CO., LTD Inventor KONG, Yirong
The present document provides a monoclonal antibody specifically binding to fibroblast growth factor receptor 2b (FGFR2b) and an antigen-binding fragment thereof, and further comprises an antibody drug conjugate (ADC), and a use of the anti-FGFR2b antibody or ADC in cancer treatment. The antibody drug conjugate comprises an anti-FGFR2 antibody or an antigen-binding fragment thereof linked to a cytotoxic agent or another component.
8.WO/2026/007901FLT3-CAR-γδT CELL CO-EXPRESSING CYTOKINE AND USE THEREOF
WO - 08.01.2026
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No PCT/CN2025/105691 Applicant PERSONGEN BIOTHERAPEUTICS (SUZHOU) CO., LTD. Inventor YANG, Lin
The present invention relates to an FLT3-CAR-γδT cell co-expressing a cytokine and a use thereof. Specifically, the present invention provides an engineered CAR-γδT cell targeting FLT3, wherein the CAR-γδT cell co-expresses an IL-2 or IL-7 cytokine, maintains a high stemness level and proliferation capacity, and has a sustained tumor cell killing ability. The FLT3-CAR-γδT cell co-expressing a cytokine of the present invention demonstrates persistent killing ability and anti-tumor activity against acute myeloid leukemia (AML) tumor cells in multiple in vitro and in vivo experiments, has high safety and wide applicability, and has application prospects in the field of AML therapy.
9.WO/2026/008891MODIFIED CROP PLANT HAVING INCREASED EXPRESSION OF ONE OR MORE ONE TRANSCRIPTION FACTORS SPECIFIC FOR THE PLANT'S ESR OR BETL
WO - 08.01.2026
Int.Class C07K 14/415
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
415from plants
 Appl.No PCT/EP2025/069311 Applicant KWS SAAT SE & CO. KGAA Inventor KOEHLER, Claudia
The present invention relates to a modified crop plant or part thereof which exhibits increased or ectopic expression of one or more one transcription factors, which one or more transcription factors are specifically expressed in the plant's ESR and/or in the plant's BETL, or modulate gene expression of one or more ESR and/or BETL-specific genes.
10.WO/2026/008066TARGETING PRKAR2B TO ENHANCE BETA-ISLET FUNCTION AND SURVIVAL FOR TREATMENTS OF DIABETES
WO - 08.01.2026
Int.Class C12N 15/85
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
 Appl.No PCT/CN2025/107151 Applicant SHANGHAI VITALGEN BIOPHARMA CO., LTD. Inventor QU, Su
A method to enhance beta-islet function and survival for treatments of diabetes by targeting PRKAR2B, and a method of preparing genetically modified human pluripotent stem cell (hPSC) in vitro, comprising providing hPSCs, with said modification comprising reducing or eliminating the expression or function of the gene products of the PRKAR2B gene in said hPSCs to be capable of differentiating in vitro to give rise to beta islets with enhanced function in glucose-stimulated insulin secretion and cell survival,are provided.
# -